|
18 Sep 2007 |
Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
|
|
18 Sep 2007 |
Pharmacopeia Initiates Phase 2 Hypertension Study with PS433540 (DARA)
|
|
18 Sep 2007 |
Hollis-Eden Pharmaceuticals Announces Filing of IND for Phase I/II Clinical Trials with HE3286 in Diseases of Inflammation
|
|
18 Sep 2007 |
Exclusive Rights to Kuvan(TM) Data Licensed to Asubio Pharma in Japan
|
|
18 Sep 2007 |
Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors
|
|
18 Sep 2007 |
Idera Pharmaceuticals Initiates Phase 1 Trial of IMO-2125 in Hepatitis C
|
|
18 Sep 2007 |
Sciele Pharma Completes Patient Enrollment for Pivotal Phase III Safety Trial for Glycopyrrolate
|
|
18 Sep 2007 |
Ligand Announces Positive Preclinical Data on Selective Androgen Receptor Modulator LGD-3303
|
|
18 Sep 2007 |
FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
|
|
18 Sep 2007 |
Metabasis Therapeutics Presents Promising Preclinical Results with Its Novel Glucagon Antagonist for the Treatment of Type 2 Diabetes
|
|
18 Sep 2007 |
NeuroSearch announces breakthrough tesofensine results from clinical Phase IIb study in obesity ("TIPO-1")
|
|
15 Sep 2007 |
FDA Approves Lilly's Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
|
|
15 Sep 2007 |
Basilea Announces Positive Top-line Data from Phase III Study of Ceftobiprole in Community-acquired Pneumonia Requiring Hospitalization
|
|
15 Sep 2007 |
FDA approves SOMA 250 mg
|
|
15 Sep 2007 |
FDA Accepts NDA Filing for Cleviprex(TM) (Clevidipine Butyrate Injectable Emulsion) for the Treatment of Acute Hypertension
|
|
14 Sep 2007 |
Lipsovir(R) - All Patients in the Phase III Program Now Enrolled
|
|
14 Sep 2007 |
Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
|
|
14 Sep 2007 |
FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
|
|
14 Sep 2007 |
Critical Therapeutics Announces Publication of Results from Two Asthma Studies
|
|
14 Sep 2007 |
AlphaRx Announces Selection of ARX828, a Novel iNOS inhibitor, for Advanced Preclinical Development
|
|
14 Sep 2007 |
Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
|
|
14 Sep 2007 |
Cytopia's FMS inhibitor prevents bone loss in animals
|
|
13 Sep 2007 |
Hollis-Eden Pharmaceuticals Reports on Anti-Inflammatory Activity with HE3286 in Models of Diseases of Inflammation
|
|
13 Sep 2007 |
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
|
|
13 Sep 2007 |
Cortex Files AMPAKINE CX717 IND for ADHD
|
